MAIA Biotechnology Presents Preclinical Data at SITC Annual Meeting Validating Efficacy of THIO in Treating Hepatocellular CarcinomaBusiness Wire • 11/15/22
MAIA Biotechnology Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateBusiness Wire • 11/09/22
MAIA Biotechnology to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsBusiness Wire • 09/29/22
MAIA Biotechnology to Participate in H.C. Wainwright 24th Annual Global Investment ConferenceBusiness Wire • 09/08/22
MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022Business Wire • 09/06/22
MAIA Biotechnology to Present Anticancer THIO Platform at XIV International Round Table on Nucleosides, Nucleotides, and Nucleic AcidsBusiness Wire • 08/30/22
MAIA Biotechnology Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateBusiness Wire • 08/22/22
MAIA Biotechnology Receives FDA Orphan Drug Designation for THIO for the Treatment of Small-Cell Lung Cancer (SCLC)Business Wire • 08/02/22